MoonLake Immunotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MLTX and other ETFs, options, and stocks.About MLTX
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases.
CEOJorge Santos da Silva
CEOJorge Santos da Silva
Employees100
Employees100
HeadquartersZug, Zug
HeadquartersZug, Zug
Founded2021
Founded2021
Employees100
Employees100
MLTX Key Statistics
Market cap1.22B
Market cap1.22B
Price-Earnings ratio-5.14
Price-Earnings ratio-5.14
Dividend yield—
Dividend yield—
Average volume5.56M
Average volume5.56M
High today$17.91
High today$17.91
Low today$17.02
Low today$17.02
Open price$17.12
Open price$17.12
Volume1.36M
Volume1.36M
52 Week high$62.75
52 Week high$62.75
52 Week low$5.95
52 Week low$5.95
Stock Snapshot
With a market cap of 1.22B, MoonLake Immunotherapeutics(MLTX) trades at $17.27. The stock has a price-to-earnings ratio of -5.14.
On 2026-01-14, MoonLake Immunotherapeutics(MLTX) stock moved within a range of $17.02 to $17.91. With shares now at $17.27, the stock is trading +1.5% above its intraday low and -3.6% below the session's peak.
Trading volume for MoonLake Immunotherapeutics(MLTX) stock has reached 1.36M, versus its average volume of 5.56M.
The stock's 52-week range extends from a low of $5.95 to a high of $62.75.
The stock's 52-week range extends from a low of $5.95 to a high of $62.75.
Analyst ratings
59%
of 17 ratingsBuy
58.8%
Hold
29.4%
Sell
11.8%
People also own
Based on the portfolios of people who own MLTX. This list is generated using Robinhood data, and it’s not a recommendation.